# OnCo record ea1131 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ea1131/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ea1131", "NCT02445391" ;
  schema:name "ECOG-ACRIN EA1131"@en ;
  schema:alternateName "EA1131"@en ;
  schema:description "EA1131 asked whether platinum chemotherapy after surgery beats capecitabine for triple-negative breast cancer that survived pre-operative chemotherapy. It was stopped early because platinum was not going to prove better and was more toxic, so capecitabine stayed the standard."@en ;
  schema:url <https://onco.cc/trials/ea1131/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02445391>, <https://doi.org/10.1002/cncr.35187>, <https://doi.org/10.1200/OA-25-00177> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:companies <https://onco.cc/companies/ecog-acrin/> ;
  onco:institutions <https://onco.cc/institutions/nci/> ;
  onco:terms <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/efs/>, <https://onco.cc/terms/tnbc-residual-disease-decision/> ;
  onco:trials <https://onco.cc/trials/create-x/>, <https://onco.cc/trials/keynote-522/> .